Naftifin, 1% 10 ml

Onychomycosis, pityriasis, epidermophytosis of large skin folds and feet, rubromycosis, trichophytosis, microsporia, skin candidiasis, mycosis with secondary bacterial infection.

Indications

– Fungal infections of the skin and skin folds (tinea corporis, tinea inquinalis);

– Interdigital mycoses (tinea manum, tinea pedum);

– Fungal infections of nails (onychomycosis);

– Skin candidiasis;

– Versicolor (pityriasis versicolor);

– Dermatomycoses (with or without accompanying itching).

Pharmacological effect

Pharmacokinetics
When used externally, it penetrates well into the skin, creating stable antifungal concentrations in its various layers, which makes it possible to use the drug once a day.

Pharmacodynamics
Naftifine is an antifungal agent for external use, belonging to the class of allylamines. The mechanism of action is associated with inhibition of squalene-2,3-epoxidase, which leads to a decrease in the formation of ergosterol, which is part of the cell wall of the fungus. Active against dermatophytes such as Trichophyton, Epidermophyton, Microsporum, molds (Aspergillus spp.), yeasts (Candida spp., Pityrosporum) and other fungi (for example, Sporothrix schenckii). Naftifine has a fungicidal effect against dermatophytes and aspergillus. Against yeast fungi, the drug exhibits fungicidal or fungistatic activity depending on the strain of the microorganism. It has antibacterial activity against gram-positive and gram-negative microorganisms that can cause secondary bacterial infections. It has an anti-inflammatory effect, which contributes to the rapid disappearance of symptoms of inflammation, especially itching.

Special instructions

The drug Naftifin is not intended for use in ophthalmology. Do not allow the drug to come into contact with the eyes.

To achieve a therapeutic effect, a course of treatment is required.

The drug Naftifin is effective in the treatment of mycoses affecting areas of the skin with hyperkeratosis, as well as in areas of hair growth.

Propylene glycol contained in the solution may cause skin irritation; If side effects occur, you should stop using the drug and consult a doctor.

Effect of the drug on the ability to drive vehicles and machinery

The drug Naftifin does not have a negative effect on the ability to drive vehicles and perform other activities that require concentration and speed of psychomotor reactions.

Active ingredient

Naftifin

Composition

For 1 ml:

Active ingredient: naftifine hydrochloride – 10 mg.

Excipients:

propylene glycol – 50 mg,

ethanol (ethyl alcohol 95%) – 400 mg,

purified water – up to 1 ml.

Pregnancy

The use of the drug during pregnancy and breastfeeding is contraindicated (the safety and effectiveness of naftifine in this category of patients has not been studied).

Contraindications

Hypersensitivity to naftifine or other components of the drug.

Pregnancy and breastfeeding (safety and effectiveness have not been established).

Application to the wound surface.

With caution

Children’s age (experience of clinical use is limited).

Side Effects

In some cases, local reactions may be observed: dry skin, skin hyperemia (redness) and burning. Side effects are reversible and do not require discontinuation of treatment. If any of the side effects indicated in the instructions worsen, or any other side effects not listed in the instructions are noted, you should immediately inform your doctor.

Interaction

Interaction with other drugs has not been studied.

Overdose

When using the drug in accordance with the instructions for use, an overdose is unlikely. In case of accidental ingestion, gastric lavage and symptomatic therapy are indicated.

Storage conditions

At a temperature not exceeding 25 °C.

Keep out of the reach of children.

Shelf life

3 years.

Do not use after the expiration date stated on the package.

Manufacturer

Tula pharmaceutical factory, Russia